Palvella Therapeutics (NASDAQ:PVLA) Trading Up 5.9% – What’s Next?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares were up 5.9% on Monday . The stock traded as high as $90.69 and last traded at $90.69. Approximately 14,713 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 252,856 shares. The stock had previously closed at $85.66.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Oppenheimer reissued an “outperform” rating and set a $200.00 price target on shares of Palvella Therapeutics in a report on Monday, December 15th. Stifel Nicolaus lifted their target price on shares of Palvella Therapeutics from $87.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, November 24th. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Chardan Capital raised their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Truist Financial boosted their price objective on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $158.69.

Palvella Therapeutics Price Performance

The firm has a market capitalization of $1.02 billion, a P/E ratio of -32.90 and a beta of -0.16. The company’s 50 day moving average price is $91.60 and its 200 day moving average price is $77.61.

Insider Buying and Selling

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds have recently added to or reduced their stakes in PVLA. Group One Trading LLC raised its holdings in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the last quarter. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics during the 3rd quarter worth approximately $28,000. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics during the third quarter worth approximately $36,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Palvella Therapeutics during the fourth quarter worth approximately $167,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Palvella Therapeutics in the second quarter valued at approximately $37,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.